|
Volumn 3, Issue 9, 2006, Pages 464-465
|
Are we taking the right approach in planning chemoprevention studies?
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ACETYLSALICYLIC ACID;
BETA CAROTENE;
BRCA1 PROTEIN;
BRCA2 PROTEIN;
CARCINOGEN;
CAROTENOID;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
PLACEBO;
TAMOXIFEN;
ANTINEOPLASTIC ACTIVITY;
BREAST CANCER;
CANCER CHEMOTHERAPY;
CANCER INHIBITION;
CANCER PREVENTION;
CANCER RESEARCH;
CANCER RISK;
CANCER SUSCEPTIBILITY;
CARDIOVASCULAR DISEASE;
CASE CONTROL STUDY;
CLINICAL TRIAL;
COLORECTAL ADENOMA;
COLORECTAL CANCER;
DAILY LIFE ACTIVITY;
DEMOGRAPHY;
DIET SUPPLEMENTATION;
DOSE RESPONSE;
DRUG EFFICACY;
ETHNOLOGY;
EVIDENCE BASED MEDICINE;
FIBER;
FOOD COMPOSITION;
GENE MUTATION;
GENETIC HETEROGENEITY;
GENETIC MARKER;
GENETIC RISK;
GENETIC SUSCEPTIBILITY;
HUMAN;
INCIDENCE;
LIFESPAN;
LIFESTYLE;
LONG TERM CARE;
LUNG CANCER;
NUTRIENT SUPPLY;
NUTRITIONAL ASSESSMENT;
OBSERVATIONAL STUDY;
PARTICIPATORY MANAGEMENT;
PATIENT COMPLIANCE;
POPULATION BASED CASE CONTROL STUDY;
PRIORITY JOURNAL;
REVIEW;
RISK ASSESSMENT;
RISK FACTOR;
RISK REDUCTION;
SMOKING;
SYSTEMATIC ERROR;
TREATMENT FAILURE;
CHEMOPREVENTION;
CLINICAL TRIALS;
HUMANS;
NEOPLASMS;
|
EID: 33748430644
PISSN: 17434254
EISSN: 17434262
Source Type: Journal
DOI: 10.1038/ncponc0535 Document Type: Review |
Times cited : (1)
|
References (10)
|